Modifying Antiretroviral Therapy in Virologically Suppressed HIV-Infected Patients

  • Author: José R. Arribas, MD (More Info)
  • Section Editor: Eric S. Daar, MD
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 10/12/18 (What's New)

Summary

  • Virologically suppressed patients with a high risk of cardiovascular disease and nephrotoxicity may need to switch to a new regimen that excludes both ritonavir and NRTIs
  • SWORD-1 and SWORD-2 trials demonstrated that switching virologically suppressed patients from various regimens to once-daily oral dolutegravir plus rilpivirine was well tolerated and noninferior to continuing baseline therapy at Week 48[Llibre 2018]
  • Preliminary data demonstrate promising outcomes with switch to raltegravir plus etravirine in virologically suppressed patients[Calin 2012; Monteiro 2014]

Action required